We have delivered a project promotional video, presentation video, judging form and a wiki. We look forward to our judging session in November!

Using the standardized form, we described the work our team did as well as what other people did for our project.

We described how and why we chose our project on our project description page!

We added documentation to an existing part on the Part's Registry page. In addition, we built upon an existing software tool by curating our SBOL tuturial videos.

We followed the steps of the engineering design cycle. Our full methodology can be found on our Engineering Success page of our wiki!

We expained how our work is responsible and good for the world.

We chose human practices as one of our special prizes because we feel we went above and beyond in documenting our thoughtful and creative approach for the development of E. esperance. Our team truly believes our project is good and responsible for the world, and reflects a community in need. Our Human Practices method included speaking with stakeholders and improving our designs off those meetings. Furthermore, our Human Practices included meeting with patients who reached out to our team wanting to share their experiences with TMAU.

Our Human Practices "Overview" page tells the story of our project and reflects the good that can be done for the TMAU community, as well as the hope we hope to bring to TMAU patients. Similarly, our Human Practices Timeline outlines these stakeholder and patient meetings, shares the learning curve our team experienced, and describes how these experiences shaped the path of our project.

Our Entrepreneurship Report shines as a testament to collaborative innovation, as we engaged with over 50 key stakeholders, spanning academia, industry, medicine, and, most notably, TMAU patients. This broad spectrum of perspectives provided invaluable insights and helped us craft an entrepreneurial plan deeply rooted in addressing an underserved community.

Patient-centricity remains at the core of our strategy, ensuring that our approach is not only technologically viable but also profoundly compassionate. What sets us apart is our unwavering commitment to feasibility and scalability; our plan for E. esperance isn't just a visionary concept but an outlined path to success. Furthermore, we've not only embraced an innovative solution but also ethical and sustainable entrepreneurship practices.

The report outlines a detailed business model, comprehensive financial analysis, and strategic partnerships, all designed to drive our project forward. At the heart of our efforts lies a clear alignment with our mission and values, reflecting a commitment to delivering tangible real-world impact. Our report presents our innovative strategy with utmost clarity and precision by highlighting the unique strengths that position us for success in addressing TMAU and, potentially, many more rare diseases in the future. With the mission addressed, we've received funding from the FSU College of Medicine's Institute for Pediatric Rare Diseases (IPRD) to continue improving our proof of concept after the Jamboree.

We chose model as our general biological engineering special prize as the model was able to help the team choose which enzymes to test in the probiotic. The model also showed how much probiotic is needed to ensure a successful treatment. The model takes into account verified data, equations, and assumptions from literature, greatly increasing its validity. In addition, the model helped the team as a whole better understand the trimethylaminuria problem by conveying information about TMA and choline through readable charts and tables.